JPH06285131A - Treating material for atopy dermatitis - Google Patents
Treating material for atopy dermatitisInfo
- Publication number
- JPH06285131A JPH06285131A JP10369693A JP10369693A JPH06285131A JP H06285131 A JPH06285131 A JP H06285131A JP 10369693 A JP10369693 A JP 10369693A JP 10369693 A JP10369693 A JP 10369693A JP H06285131 A JPH06285131 A JP H06285131A
- Authority
- JP
- Japan
- Prior art keywords
- atopic dermatitis
- water
- silver
- zinc
- therapeutic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Devices For Medical Bathing And Washing (AREA)
Abstract
Description
【０００１】[0001]
【産業上の利用分野】本発明は、アトピー性皮膚炎治療
材に関し、特に入浴時に使用するアトピー性皮膚炎治療
材に関するものである。BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a therapeutic material for atopic dermatitis, and more particularly to a therapeutic material for atopic dermatitis used during bathing.
【０００２】[0002]
【従来の技術と問題点】アトピー性皮膚炎とは、アレル
ギー体質者が何らかの原因で罹病する皮膚炎であり、皮
膚にかゆみや炎症が生じ、血漿が滲出し、重症となると
血漿に加えて膿と血が身体全体から滲出し、かゆみや炎
症等のため睡眠が取れず、このため病気一般に対する抵
抗力が低下し、感染症に罹り易くなるという症状を呈す
るものである。[Prior Art and Problems] Atopic dermatitis is dermatitis that allergic persons are affected by for some reason. Itching and inflammation occur in the skin, and when plasma is exuded and becomes severe, pus is added to the plasma. And blood oozes from the whole body, and sleep is not possible due to itchiness, inflammation, etc. Therefore, resistance to general illness is reduced, and infection is more likely to occur.
【０００３】従来この病気の治療薬としてはステロイド
剤（副腎皮質ホルモン）が使用されているが、対症療法
としては効果があるが、一旦これに依存すると次回の発
症時には必ず以前より悪化したステロイド皮膚疾患に進
展する傾向がある。これは、ステロイド剤の投与によ
り、副腎機能が低下してしまい、副腎皮質ホルモン欠乏
による皮膚炎を併発せざるを得ないからであるといわれ
ている。従ってステロイド剤を長期に亘り使用すること
は生体系のバランスを保つ上で好ましいことではなく、
ステロイド剤使用量の減量の対策が求められる。また抗
ヒスタミン剤もよく使用されるところであるが、対症療
法薬剤としての効果は弱い。Conventionally, a steroid drug (adrenocortical hormone) has been used as a therapeutic drug for this disease, but it is effective as a symptomatic treatment, but once it depends on it, the steroid skin is always worse than before at the next onset. Tends to develop disease. It is said that this is because the administration of steroids causes a decrease in adrenal function, which inevitably causes dermatitis due to adrenocortical hormone deficiency. Therefore, long-term use of steroids is not preferable in maintaining the balance of the biological system,
Measures to reduce the amount of steroids used are required. Antihistamines are also often used, but their effectiveness as symptomatic drugs is weak.
【０００４】このように、アトピー性皮膚炎は、アレル
ギー体質を変更しない限り根本的な治療は困難であり、
現在のところ決定的治療法は無く、各種の併用療法が用
いられている。その一つとして、温泉湯治療法が有効で
あることが指摘されている。その機序については明白で
はないが、温熱による血行循環と新陳代謝の促進と含有
化学成分の皮膚接触及び皮膚への浸透による治療効果で
あるとされている。As described above, atopic dermatitis is difficult to be fundamentally treated unless the allergic constitution is changed,
Currently there is no definitive treatment and various combination therapies are used. As one of them, it has been pointed out that the hot spring treatment method is effective. Although the mechanism is not clear, it is considered to be a therapeutic effect by promoting circulation of blood and metabolism by heat and contacting and penetrating the contained chemical components into the skin.
【０００５】しかし、温泉湯治を長期に続けることは経
済的に負担が大きく、家庭内で治療することが望まれる
が、「湯の華」や「温泉の素」等の入浴剤は、温泉含有
成分の一部であり、これを淡水に解かしたからといって
温泉効果が得られるものでもない。温泉による効果は単
に温泉中に溶解した物質成分によるものだけではなく、
複雑なメカニズムがあると考えられている。温泉水をポ
リエチレン容器に入れて宅配することも普及しつつあ
り、これは人工あるいは天然の入浴剤では代替出来ない
性質が自然の温泉水にあるからである。しかし、温泉水
の宅配も経済的負担は大きく、遠方の場合は、温泉水の
皮膚に対する生理活性力が変化し効果が減少する。However, it is economically burdensome to continue the hot spring treatment for a long period of time, and it is desirable to treat it at home. However, bathing agents such as "Yu no Hana" and "Onsen no Moto" are components of the hot spring. It is a part, and even if it is dissolved in fresh water, it does not mean that the hot spring effect is obtained. The effect of the hot spring is not only due to the substance components dissolved in the hot spring,
It is believed that there are complex mechanisms. Delivery of hot spring water in polyethylene containers for home delivery is also becoming popular because natural hot spring water has a property that artificial or natural bath agents cannot substitute. However, home delivery of hot spring water also has a large economic burden, and in the case of a distant place, the physiological activity of the hot spring water on the skin changes and the effect decreases.
【０００６】[0006]
【発明の目的】本発明は以上の点に鑑み、大きな経済的
負担無しに、温泉湯治と同様なアトピー性皮膚炎の治療
を行える治療材を提供しようとするものである。SUMMARY OF THE INVENTION In view of the above points, the present invention is to provide a therapeutic material capable of treating atopic dermatitis similar to hot spring spa treatment without a large economic burden.
【０００７】[0007]
【問題点を解決するための手段】本発明は、担体である
人工又は天然の無機素材に、銀、銅または亜鉛のいずれ
かあるいはその組み合わせを担持させたことを特徴とす
るアトピー性皮膚炎治療材である。本発明の無機素材
は、人工又は天然のセラミック材あるいは人工又は天然
のゼオライト、アルミナ、酸化珪素、アルミノ硅酸塩、
シリカ、酸化チタン、マグネシアから選ばれた１種また
は２種以上の素材からなり、多孔質のセラミック材とす
るのが望ましい。ただし、天然の焼成物質もセラミック
材に含まれるものとする。その形態は固形、顆粒状、粉
末状等使用状態に応じていろいろの形態を取り得る。DISCLOSURE OF THE INVENTION The present invention is a therapeutic treatment for atopic dermatitis characterized in that an artificial or natural inorganic material as a carrier is loaded with one of silver, copper or zinc or a combination thereof. It is a material. The inorganic material of the present invention is an artificial or natural ceramic material or an artificial or natural zeolite, alumina, silicon oxide, aluminosilicate,
It is desirable to use a porous ceramic material made of one or more materials selected from silica, titanium oxide and magnesia. However, natural fired substances are also included in the ceramic material. The form thereof may be various forms such as solid form, granular form and powder form depending on the use condition.
【０００８】かかる無機素材に、銀、銅または亜鉛のい
ずれかあるいはその組み合わせが担持させられるが、そ
の担持方法としては以下のようにいくつかの手段が発表
されている。但し本発明はこれらの担持方法に限定され
るものではない。その手段の１つはイオン交換処理によ
り担持させることを含む。たとえば、天然又は人工のゼ
オライトを銀イオンで処理し、ゼオライト中のナトリュ
ウムを銀で置換固定化する方法があり、同様な方法で他
の無機素材に銀その他が担持され得る。[0008] Any one of silver, copper or zinc or a combination thereof is supported on such an inorganic material, and as the supporting method, some means have been announced as follows. However, the present invention is not limited to these loading methods. One of the means involves loading by ion exchange treatment. For example, there is a method in which natural or artificial zeolite is treated with silver ions and the sodium in the zeolite is replaced and fixed with silver, and silver or the like can be supported on other inorganic materials by the same method.
【０００９】このほかに、コーティングによって上記無
機素材に銀、銅、亜鉛のいずれか又はその組合せを担持
させる方法がある。この場合、バインダーを用い銀、銅
または亜鉛のいずれかあるいはその組合せを無機素材に
固定化する。バインダーの一例としては、一般式ＲＳｉ
（ＯＲ’）（Ｒは炭素数１〜８の有機基、Ｒ’はアルキ
ル基又はアシル基）で示されるオルガノアルコキシシラ
ン、その加水分解物及び／またはその部分縮合物があ
る。さらに、上記無機素材に、一般式Ｍ2 Ｏ・ｎＳｉＯ
2 ・ｍＨ2 Ｏ（Ｍは１価の金属原子または第３級もしく
は第４級アンモニウム）で表わされるケイ酸塩に、亜
鉛、水酸化アルミニウムなどを硬化剤として用い、加熱
下、銀、銅、亜鉛のいずれかあるいはその組合せを固定
化する方法もある。In addition to the above, there is a method in which any one of silver, copper, zinc, or a combination thereof is supported on the above inorganic material by coating. In this case, a binder is used to immobilize either silver, copper, or zinc or a combination thereof on an inorganic material. As an example of the binder, a general formula RSi is used.
(OR ′) (R is an organic group having 1 to 8 carbon atoms, R ′ is an alkyl group or an acyl group), an organoalkoxysilane, a hydrolyzate thereof, and / or a partial condensate thereof. Furthermore, the above-mentioned inorganic material is added to the general formula M 2 O · nSiO.
A silicate represented by 2 · mH 2 O (M is a monovalent metal atom or a tertiary or quaternary ammonium) is used with zinc, aluminum hydroxide or the like as a curing agent, and silver, copper, There is also a method of immobilizing either zinc or a combination thereof.
【００１０】かかる治療材は、加工により、球状、直方
体、顆粒状、粉状など種々の形態で利用されるが、水に
接触させ、浴湯とともに使用される。浴湯に作用させる
ためには、固体として浴槽の底に設置して使用する。通
常、本材をスリットが設けられた通水性のある筐体内に
収納し、浴槽内に沈めて浴湯に接触させて使用してもよ
いし、固体を浴槽の循環水路に置き強制的に水接触体と
して設置してもよい。また、本材を繊維状に加工し浴槽
の循環水路に置き強制的に水接触体として設置させても
よい。The therapeutic material is used in various forms such as spherical shape, rectangular parallelepiped shape, granular shape, and powder shape by processing, and it is used in contact with water and together with bath water. In order to act on the bath water, it is installed as a solid at the bottom of the bath and used. Usually, this material may be stored in a water-permeable housing with slits and then used by being immersed in a bathtub and brought into contact with the bath water. You may install as a contact body. Alternatively, the material may be processed into a fibrous form, placed in a circulating water channel of a bathtub and forcibly installed as a water contact body.
【００１１】このように本発明は、最終的には銀、銅ま
たは亜鉛のいずれかあるいはその組み合わせを担持させ
た無機素材を水、特に湯水に接触して使用することによ
り、今日まで的確な治療法の無かったアトピー性皮膚炎
に優れた治療効果を可能としたことに特長がある。As described above, according to the present invention, finally, by using an inorganic material carrying any one of silver, copper and zinc or a combination thereof in contact with water, especially hot and cold water, an accurate treatment has been achieved to date. It is characterized in that it has an excellent therapeutic effect on atopic dermatitis, which had no method.
【００１２】[0012]
【実施例】シリカ、酸化チタン、マグネシアの混合物を
素材として多孔質の担体を製造し、これにオルガノアル
コキシシラン１００重量部、親水性有機溶剤１５０重量
部、水８０重量部、ゼオライト１００重量部、銀１０重
量部からなるコーティング組成物を塗付して、本アトピ
ー性皮膚炎治療材を得た。これを、通常の水道水を張っ
た家庭用浴槽の底に沈め、一般的な入浴湯温を設定、患
者を入浴させアトピー性皮膚疾患に対する効果を経日的
に観察した。特にアトピー性皮膚炎に特徴的な皮膚の
痒み、皮膚のかさかさ感、皮膚の赤みを評価項目と
して効果を観察した。[Example] A porous carrier was produced using a mixture of silica, titanium oxide and magnesia as a raw material, and 100 parts by weight of organoalkoxysilane, 150 parts by weight of hydrophilic organic solvent, 80 parts by weight of water, 100 parts by weight of zeolite, A coating composition consisting of 10 parts by weight of silver was applied to obtain the present therapeutic material for atopic dermatitis. This was submerged in the bottom of a domestic bathtub filled with ordinary tap water, a general bathing water temperature was set, the patient was bathed, and the effect on atopic skin disease was observed daily. In particular, the effects were observed using the itching of the skin, the bulkiness of the skin, and the redness of the skin, which are characteristic of atopic dermatitis, as evaluation items.
【００１３】(1) 実験者：２３歳の男性 実験者は１年前より抗ヒスタミン剤の内服と酪酸プロピ
オン酸ヒドロコルチゾン（ＨＢＰ軟膏）の外用を行って
きたが、中程度のかゆみ、乾燥状態、軽度の潮紅が残っ
ていた。本治療材を浴槽内に設置し、毎日入浴させたと
ころ、使用１週後からかゆみ・乾燥状態、赤みに軽度の
改善が視認され、２週後からかゆみはほぼ消失、赤みも
消え皮膚状態は全身が軽快し始めた。(1) Experimenter: A 23-year-old male experimenter had been taking an antihistamine and taking hydrocortisone butyrate (HBP ointment) externally for 1 year. The hot flush was left. When this therapeutic material was placed in a bathtub and bathed daily, a slight improvement in itchiness / dryness and redness was visually recognized after 1 week of use, and itchiness had almost disappeared and redness had disappeared after 2 weeks The whole body began to lighten.
【００１４】(2) 実験者：２１歳の男性 実験者は６ケ月前より抗ヒスタミン剤の内服とＨＢＰ軟
膏の外用を行ってきたが、軽度のかゆみ、乾燥状態、軽
度の潮紅が残っていた。そこで本治療材を浴槽内に設置
し、毎日の入浴させたところ、使用１週後からかゆみが
消失し、皮膚の乾燥が改善され、以後若干の変動を示し
ながら、良好な経過を示した。皮膚の赤みは、使用前に
比し、少し消失の程度であったが、外用軟膏の使用は半
分以下となり、明らかな改善が認められた。(2) Experimenter: 21-year-old male The experimenter had been taking antihistamines and externally applying HBP ointment for 6 months, but slight itchiness, dryness and mild flushing remained. Therefore, when the present therapeutic material was placed in a bath and bathed every day, the itch disappeared from one week after use, the dryness of the skin was improved, and a slight change thereafter was observed, showing a good progress. The redness of the skin was slightly less than that before use, but the use of the external ointment was less than half, and a clear improvement was observed.
【００１５】(3) 実験者：２６歳の女性 ２０歳の頃から軽度のアトピー性皮膚炎に罹病してお
り、２ケ月まえから抗ヒスタミン剤の内服とＨＢＰ軟膏
の外用が行われてきた。完治しないため、本治療材を使
用して毎日入浴させたところ、使用１週後からかゆみが
軽くなり、２週目以後には完全に消失した。皮膚の乾燥
も改善され、赤みも少し消えた。(3) Experimenter: 26-year-old woman Affected by mild atopic dermatitis since the age of 20, and oral anti-histamines and HBP ointment have been applied externally from two months ago. Since this treatment did not completely cure, he took a bath every day using this therapeutic material, and the itch became light one week after the use, and completely disappeared after the second week. The dryness of the skin was improved and the redness disappeared a little.
【００１６】(4) 実験者：６６歳の女性 ５年前から慢性湿疹で激しい掻破痕を形成し眠れない日
が続いたため、抗アレルギー剤の内服と”Ｓｔｒｏｇｅ
ｓｔ”として評価されているステロイド剤であるプロピ
オン酸クロベタゾール（ＤＰ軟膏）の外用が行われてき
たが瘡痒は軽快しなかった。そこで本治療材を使用さ
せ、毎日の入浴させたところ、使用１週後にはかゆみに
変化が見られなかったが、２週目から明らかにかゆみの
軽減が見られた。皮膚の乾燥は、３週目までは使用前よ
りややよくなった程度であるが、４週目にはかさかさ感
が消失した。皮膚の赤みは１週後より少し消失し、２週
後には完全に消えた。(4) Experimenter: A 66-year-old woman 5 years ago, she had been suffering from chronic scars and had severe scars, and she could not sleep.
Clobetasol propionate (DP ointment), which is a steroid drug evaluated as “st”, has been used externally, but itching did not improve. Therefore, when this therapeutic material was used and bathed daily, it was used. There was no change in itchiness after 1 week, but the itchiness was clearly reduced from the 2nd week, and the dryness of the skin was slightly better than before use by the 3rd week, The bulkiness disappeared at 4 weeks, the redness of the skin disappeared slightly after 1 week, and completely disappeared after 2 weeks.
【００１７】[0017]
【発明の効果】以上のごとく、本発明に係るアトピー性
皮膚炎治療材は、副作用のない安全な治療材で、その疾
患に対して究めて良好な治療効果を有することが確認さ
れた。その機序は定かではないが、水あるいは温湯が本
治療材に接触することにより、皮膚に対して活性を示す
活性水となり、通常の温泉水のように温熱作用とこの活
性水の皮膚への活発な接触が総合的に作用し、病理上好
影響をもたらすものと推測される。すなわち、本発明に
係るアトピー性皮膚炎患者にとって極めて苦痛な痒みを
減少し消滅させ、更には健康な皮膚への回復を促進する
作用のあることが明らかとなった。また、アトピー性皮
膚炎治療の対症療法剤としてステロイド剤の使用量の軽
減、ステロイド剤使用からの脱離を促進する上からも本
発明の意義は大きい。As described above, it was confirmed that the therapeutic material for atopic dermatitis according to the present invention is a safe therapeutic material with no side effects and has an excellent therapeutic effect on the disease. The mechanism is not clear, but when water or warm water comes into contact with this therapeutic material, it becomes active water that is active on the skin, and like normal hot spring water, it has a heating effect and this active water on the skin. It is speculated that active contact acts comprehensively and has a positive pathological effect. That is, it has been clarified that it has an action of reducing and eliminating itching, which is extremely painful for atopic dermatitis patients according to the present invention, and further promoting recovery to healthy skin. Further, the present invention is also significant in terms of reducing the amount of steroid used as a symptomatic agent for the treatment of atopic dermatitis and accelerating the withdrawal from the use of steroid.
Claims (8)
亜鉛のいずれかあるいはその組み合わせを担持させたこ
とを特徴とするアトピー性皮膚炎治療材1. A therapeutic material for atopic dermatitis, characterized in that an artificial or natural inorganic material is loaded with one or a combination of silver, copper and zinc.
セラミック材であることを特徴とする請求項１のアトピ
ー性皮膚炎治療材2. The atopic dermatitis therapeutic material according to claim 1, wherein the inorganic material is a porous artificial or natural ceramic material.
酸化珪素、アルミノ硅酸塩、シリカ、酸化チタン、マグ
ネシアから選ばれた１種または２種以上の素材からなる
ことを特徴とする請求項１のアトピー性皮膚炎治療材3. The inorganic material is zeolite, alumina,
The atopic dermatitis therapeutic material according to claim 1, which is made of one or more materials selected from silicon oxide, aluminosilicate, silica, titanium oxide, and magnesia.
れかあるいはその組み合わせをイオン交換処理により担
持させたことを特徴とする請求項１のアトピー性皮膚炎
治療材4. The therapeutic material for atopic dermatitis according to claim 1, wherein any one or a combination of silver, copper and zinc is carried on the inorganic material by an ion exchange treatment.
ィングにより銀、銅または亜鉛のいずれかあるいはその
組み合わせをバインダーを用いコーティングにより担持
させたことを特徴とする請求項１のアトピー性皮膚炎治
療材5. The therapeutic material for atopic dermatitis according to claim 1, wherein the inorganic material is coated with a binder to carry any one or a combination of silver, copper and zinc by using a binder.
ン、その加水分解物及び／またはその部分縮合物、及び
親水性有機溶剤を含むことを特徴とする請求項５のアト
ピー性皮膚炎治療材6. The therapeutic material for atopic dermatitis according to claim 5, wherein the binder contains an organoalkoxysilane, a hydrolyzate and / or a partial condensate thereof, and a hydrophilic organic solvent.
組み合わせを担持させた無機素材を水に接触させその水
で治療することを特徴とするアトピー性皮膚炎治療方法7. A method for treating atopic dermatitis, which comprises contacting an inorganic material supporting silver, copper or zinc or a combination thereof with water and treating with the water.
項７のアトピー性皮膚炎治療方法8. The method for treating atopic dermatitis according to claim 7, wherein the water is a bath water.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP10369693A JPH06285131A (en) | 1993-04-07 | 1993-04-07 | Treating material for atopy dermatitis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP10369693A JPH06285131A (en) | 1993-04-07 | 1993-04-07 | Treating material for atopy dermatitis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH06285131A true JPH06285131A (en) | 1994-10-11 |
Family
ID=14360944
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP10369693A Pending JPH06285131A (en) | 1993-04-07 | 1993-04-07 | Treating material for atopy dermatitis |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH06285131A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH09157155A (en) * | 1995-12-14 | 1997-06-17 | 邦明 ▲高▼松 | Silicon bath material |
| DE102008031023A1 (en) | 2008-06-30 | 2009-12-31 | Neubourg Skin Care Gmbh & Co. Kg | Foam skin care cream |
| KR101108986B1 (en) * | 2008-10-27 | 2012-01-31 | 김완겸 | Composition and Coating method for Fiber with Prevention of atopicdermatitis |
-
1993
- 1993-04-07 JP JP10369693A patent/JPH06285131A/en active Pending
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH09157155A (en) * | 1995-12-14 | 1997-06-17 | 邦明 ▲高▼松 | Silicon bath material |
| DE102008031023A1 (en) | 2008-06-30 | 2009-12-31 | Neubourg Skin Care Gmbh & Co. Kg | Foam skin care cream |
| KR101108986B1 (en) * | 2008-10-27 | 2012-01-31 | 김완겸 | Composition and Coating method for Fiber with Prevention of atopicdermatitis |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Zimmerman et al. | Concomitant pilocarpine during head and neck irradiation is associated with decreased posttreatment xerostomia | |
| Mahattanakul et al. | Treatment of chronic inflammatory demyelinating polyneuropathy with cyclosporin-A. | |
| JPS59155313A (en) | Selective weight control treatment | |
| Callaway et al. | Cutaneous conditions observed in patients during treatment with lithium | |
| Smith et al. | Allopurinol and urolithiasis | |
| JPH06285131A (en) | Treating material for atopy dermatitis | |
| Huang et al. | Acupuncture stimulation of ST‐36 (Zusanli) significantly mitigates acute lung injury in lipopolysaccharide‐stimulated rats | |
| Peden et al. | Ranitidine in the treatment of duodenal ulceration | |
| WO1989000856A1 (en) | Pharmaceutical combination for treatment of bone-wasting diseases | |
| US3705946A (en) | Method of treating hyperuricemia | |
| HETZEL et al. | Studies of serum long‐acting Thyroid stimulator (LATS) in relation to exophthalmos after therapy for thyrotoxicosis | |
| Perlmutter et al. | The chronically reserpinized rat as a possible model for cystic fibrosis. VII. Alterations in the secretory response to cholecystokinin and to secretin from the pancreas in vivo | |
| Gower | HAE update: determining optimal patient specific therapy. | |
| Miano et al. | Allopurinol in the prevention of calcium oxalate renal stones | |
| CN1069196C (en) | Application of rifampicin in linxiao'an medicine for treating gonorrhea | |
| JPH1160456A (en) | Bathing agent for skin and skin preparation for external use and body soap | |
| SOMERVILLE et al. | Actinomycin D in the treatment of Paget's disease of bone | |
| Bruni et al. | Open issues in anorexia nervosa: Prevention and therapy of bone loss | |
| Wenhe et al. | The effect of electric acupuncture treatment on urinary MHPG-sulphate excretion in unmedicated schizophrenics | |
| Annunziato et al. | Proceedings: Catecholaminergic control of thyroid stimulating hormone (TSH) and adrenocroticotrophic hormone (ACTH) secretion. | |
| Kersley et al. | Hypoglycaemia in treatment of rheumatoid arthritis | |
| Rose et al. | Effect of dihydrotachysterol in treatment of parathyroid deficiency | |
| Blitz et al. | Pain attenuation by contralateral cold stimulation | |
| Freeman | Southwestern Internal Medicine Conference: Paget’s disease of bone | |
| Ghormley et al. | The use of aluminum acetate in the treatment of malacic diseases of bone |